Latest Breaking News On - Jonathon li - Page 1 : comparemela.com

One in five patients experience rebound COVID after taking Paxlovid, new study finds

One in five patients experience rebound COVID after taking Paxlovid, new study finds
sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.

Harvard universityUnited statesYijia liMamadou barryAmyk barczakDessie tienZachary wallaceRockib uddinMark siednerJacobe lemieuxSarahp hammondManishc choudharyYumeko kawanoJonathon liRebeccaf gilbertGregorye edelstein

One in five patients experience rebound COVID

<p>A new study by investigators from <a href="https://www.massgeneralbrigham.org/">Mass General Brigham</a> found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test—a phenomenon known as virologic rebound. By contrast, people not taking Paxlovid only experienced rebound about 2 percent of the time. Results are published in <a href="https://www.acpjournals.org/journal/aim/authors1"><em>Annals of Internal Medicine</em></a>.</p>

Harvard universityUnited statesShruti sagarManishc choudharySarahp hammondMark siednerMamadou barryYumeko kawanoZachary wallaceRockib uddinGregorye edelsteinJacobe lemieuxDessie tienRebeccaf gilbertJonathon liZahra reynolds

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test-;a phenomenon known as virologic rebound.

United statesMark siednerJonathon liDivision of infectious diseases at brighamDivision of infectious diseases at massachusettsMass general brighamInfectious diseasesMassachusetts generalPost vaccination viral characteristics studyClinical trialCovid 19Infectious diseasesArs cov 2

Over 20% COVID-infected people taking Paxlovid experience viral rebound: Study, ET HealthWorld

People not taking Paxlovid experienced the viral rebound phenomenon only about two per cent of the time, the researchers at the Mass General Brigham hospital, Boston, US, found. Paxlovid, which is a Nirmatrelvir-ritonavir therapy taken orally, has been previously studied to be effective in reducing hospitalisation and death in severe COVID-19 infections.

New delhiUnited statesJonathon liMark siednerDivision of infectious diseases at massachusettsWorld health organisationMass general brighamInfectious diseasesMassachusetts generalCovid 19World health organizationAnnals of internal medicineDivision of infectious diseasesMassachusetts general hospitalHealth news

COVID Rebound Occurs in 1 in 5 People Taking Paxlovid

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test a phenomenon known as virologic rebound.

United statesMark siednerJonathon liHealthday newsMassachusetts general hospitalMass generalCovid based therapy